The 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025), held in Amsterdam 19–22 March, once again set the stage for groundbreaking advancements in diabetes management. As the field rapidly evolves, this year’s meeting showcased cutting-edge research in continuous glucose monitoring, automated insulin delivery, and disease-modifying therapies. In this article, we delve into the key takeaways from the meeting, exploring how these innovations could transform the future of diabetes management.
Performance and accuracy of 15-day G7 continuous glucose monitor
A new study presented during the Hot from the Oven plenary session suggests that the investigational 15-day Dexcom G7 integrated continuous glucose monitor (iCGM) is both accurate and safe for adults with diabetes. As CGM technology plays an increasing role in diabetes management, this prospective, multicentre study aimed to assess the performance of the extended-wear G7 iCGM.
The trial (ClinicalTrials.gov identifier: NCT05263258) enrolled 130 adults with type 1 (T1D) or type 2 diabetes (tT2D) across six US clinical sites. Over a 15.5-day period, participants attended four in-clinic sessions where glucose values from the G7 iCGM were compared with frequent blood glucose measurements from a laboratory-standard analyser. The accuracy of the device was evaluated using key metrics, including the mean absolute relative difference (MARD) and percentage agreement within predefined glucose ranges.1
Results showed that the G7 iCGM had an overall MARD of 8.0%, with 87.7% of sensor readings falling within 15 mg/dL or 15% of reference values, meeting and exceeding regulatory performance benchmarks for iCGM systems. Agreement rates within 20%, 30%, and 40% of reference values were 94.2%, 98.9%, and 99.8%, respectively. Participants reported a positive user experience, and no serious adverse events were recorded.
The 15-day Dexcom G7 CGM maintained consistent accuracy and safety throughout its wear period, offering a longer-duration option for glucose monitoring. With fewer sensor changes and strong performance metrics, the device could support more convenient diabetes management. These findings reinforce the potential of extended-use CGMs in improving continuous glucose monitoring for people with diabetes.
Efficacy of the Omnipod® 5 automated insulin delivery system compared with multiple daily injections in type 1 diabetes: A multinational randomized controlled trial (RADIANT)
Managing T1D remains a challenge for many, as multiple daily injections (MDI) often result in suboptimal blood sugar control. The Omnipod® 5 automated insulin delivery (AID) system offers an alternative, but its benefits over MDI have yet to be fully established. At the meeting, investigators shared data from the RADIANT study (ClinicalTrials.gov identifier: NCT05923827), a randomized controlled trial assessing the direct transition from MDI to the Omnipod® 5 AID system in children and adults with T1D.2
The study enrolled 188 participants (4–70 years of age) with T1D ≥1 year and screening HbA1c 7.5–11% (58–97mmol/mol) across France, the UK, and Belgium, all of whom had been using MDI with a FreeStyle Libre 2 continuous glucose monitor (CGM) for at least 3 months. After a 2-week data collection period, participants were randomly assigned (2:1) to either switch to the Omnipod 5 system or continue with MDI and CGM for 13 weeks. Researchers primarily measured changes in HbA1c, a key marker of long-term blood sugar control, while also evaluating CGM-based metrics and patient-reported outcomes.
The results showed a significant improvement in blood sugar control for those using the AID system. Participants saw their average HbA1c drop from 8.1% to 7.2% in 3 months. Time spent in the target glucose range (70–180 mg/dL) increased from 39% to 65%, meaning those in the AID group spent an additional 5.4 hours per day within target glucose range compared with MDI. Importantly, these improvements were achieved without an increase in hypoglycaemia.
These findings highlight the potential of the Omnipod 5 system to enhance glucose management and quality of life for people with T1D, offering a more effective and automated alternative to traditional injection therapy.
Study results: A randomized, controlled trial of Control-IQ+ technology in type 2 diabetes (The 2IQP Study)
At ATTD 2025, Tandem presented findings from the 2IQP Study (ClinicalTrials.gov identifier: NCT05785832), a randomized, controlled trial evaluating the role of automated insulin delivery (AID) systems in adults with insulin-treated T2D. While AID systems are well-established for T1D, their effectiveness in T2D remains less explored.
In this 13-week, multicentre study, 319 participants were randomly assigned to either an AID system or their usual insulin regimen, with both groups using continuous glucose monitoring (CGM). The results showed that those using AID experienced a greater improvement in blood sugar control. Haemoglobin A1c levels, a key marker of long-term glucose management, dropped by 0.9 percentage points in the AID group compared to 0.3 percentage points in the control group. Additionally, participants using AID spent significantly more time within the target glucose range (64% vs. 52%).3
Importantly, both groups had low rates of hypoglycaemia, with only one severe event reported in the AID group. These findings highlight the potential of AID systems to enhance diabetes management for individuals with insulin-treated T2D, though longer-term studies are needed to confirm the benefits and assess real-world implementation.
Effect of Teplizumab on time in range in newly diagnosed type 1 diabetes: A PROTECT study per-protocol analysis
Teplizumab, an immunotherapy designed to slow the progression of T1D, has shown promise in preserving beta-cell function in newly diagnosed patients. In the PROTECT (ClinicalTrials.gov identifier: NCT03875729) trial, researchers evaluated whether teplizumab could also improve blood sugar control by increasing the time spent within a healthy glucose range.
The study included children and adolescents ( 8–17 years of age) with newly diagnosed stage 3 T1D. Participants received either teplizumab or a placebo in two 12-day treatment courses, 26 weeks apart. Researchers monitored glucose levels continuously to assess how much time patients spent in the target range (70–180 mg/dL) compared with hyperglycaemic or hypoglycaemic states.4
The results showed that teplizumab-treated participants spent significantly more time within the target glucose range compared to those receiving placebo, with a modest but meaningful increase of 6.17% at week 78. Additionally, while time spent in high and very high glucose levels was lower in the teplizumab group, the differences were not statistically significant. Importantly, there was no increase in time spent in hypoglycaemia, suggesting that teplizumab improved glucose control without raising the risk of dangerously low blood sugar levels.
These findings suggest that teplizumab may help patients newly diagnosed with T1D achieve better glycaemic stability over time. While the improvements in hyperglycaemia require further confirmation, the therapy appears to support more consistent blood sugar control without additional safety concerns.
References:
- Garg SK, Bailey TS, Castorino K, et al. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025; Epub ahead of print.
- gov. Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults (RADIANT). ClinicalTrials.gov identifier: NCT05923827. Available at: https://clinicaltrials.gov/study/NCT05923827 (accessed 27 March 2025).
- Kudva YC, Raghinaru D, Lum JW, et al. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. 2025; Epub ahead of print.
- gov. Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT). ClinicalTrials.gov identifier: NCT03875729. Available at: https://clinicaltrials.gov/study/NCT03875729 (accessed 27 March 2025).
Disclosures: This article was created by the touchENDOCRINOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.
Editor: Carla Junkier, Editorial Director
Cite: ATTD 2025: Key Breakthroughs in Diabetes Technology and Treatment. touchENDOCRINOLOGY. 10 April 2025.
Further content in diabetes
